Mitra Keluarga Karyasehat (MIKA): IDR 2,850— BUY, SSI TP: IDR 3,300 (from 3,000); Cons. TP: IDR 3,200

SAMUEL SEKURITAS INDONESIA
Your Lifelong Investment Partner

3Q24 Results (IDR Bn)	3Q24	3Q23	QoQ (%)	YoY (%)	9M24	9M23	YoY (%)	9M24/ SSI (%)	9M24/ Cons. (%)
Revenue	1,166	1,108	(3.6)	5.3	3,619	3,157	14.6	74.7	73.4
Gross Profit	623	557	(4.5)	12.0	1,942	1,573	23.5	78.2	75.6
Operating Profit	345	327	(12.0)	5.4	1,179	908	29.9	83.6	77.5
EBITDA	428	398	(9.3)	7.4	1,364	1,125	21.2	77.4	74.3
Net Profit	272	233	(12.6)	16.9	873	686	27.2	78.0	74.0
Key Ratios									
GPM (%)	*53.4*	*50.2*	-	-	*53.6*	*49.8*	-	-	-
OPM (%)	*29.5*	*29.5*	-	-	*32.6*	*28.7*	-	-	-
EBITDA Margin (%)	*36.7*	*39.0*	-	-	*35.2*	*35.6*	-	-	-
NPM (%)	*23.3*	*21.0*	-	-	*24.1*	*21.7*	-	-	-

SWOT Analysis of the Results (In-Line)

Strength
Increased demand for high-Intensity treatments in outpatient (+5.1% QoQ) and inpatient (+1.7% QoQ) segments, alongside +3.1% QoQ growth in overall volume, supported MIKA's top-line; 9M24 EBITDA margin expanded to 37.7% (9M23: 35.6%) on the back of favorable payer mix (85% non-JKN in 9M24 vs. 81% in 9M23)

Weakness
Inpatient traffic saw -6.3% QoQ decline in 3Q24, primarily due to temporary halt in cashless payment programs by some insurance companies in July, though the program resumed in August following negotiations

Opportunity
Expectations of favorable payer mix and organic increase in treatment intensity should pave the way for robust margins onwards; stock underperformance provides buying opportunities

Threat
Tighter balance sheet, stemming from increased reimbursement demands to JKN and insurance companies, combined with weak purchasing power, could restrict ASP growth and dampen overall patient traffic; relatively demanding valuation of 20.7 EV EBITDA (local peers avg: 15.9x) could negatively further impact stock performance

Peer Comparables

Company Ticker	Rating	Last Price (IDR)	Target Price (IDR)	Market Cap (USD Mn)	2024F EPS Growth (%)	P/B (x)	P/E (x)	EV/EBITDA (x)	ROE (x)
301267 CH		N.A		2,527	6.1	2.9	25.6	13.6	11.4
KIMS IN		N.A		2,608	16.8	9.8	60.5	30.8	17.5
RAINBOW IN		N.A		1,948	17.0	11.1	64.5	33.8	18.1
MIKA IJ		2,850	3,300	2,507	28.6	6.0	33.8	20.7	19.2
SILO IJ		3,140	U.R*	2,552	(1.4)	4.6	33.6	13.0	14.2
HEAL IJ		1,450	1,800	1,429	41.1	4.9	34.8	14.0	13.5
Sector				***13,571***	***16.1***	***6.5***	***41.9***	***21.0***	***15.7***

*** Under-Review**

Relative YTD Performance vs JCI



Sources: Company, Bloomberg, SSI Research

Analysts: Jonathan Guyadi, Belva Monica